Immunic Inc (IMUX)
Healthcare
Biotechnology
14.00 $
-0.1%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Immunic Inc (IMUX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 86.9% of the shares are freely tradable; institutional investors hold 46.9%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
46.9%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
1.0%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
86.9%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
12.7%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
14Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Bvf Inc | 5.62 | 7,652,972 | +0.0 | 03/31/2026 |
| Vanguard Capital Management, LLC | 3.77 | 5,138,316 | +0.0 | 03/31/2026 |
| Vanguard Group Inc | 3.69 | 5,020,337 | +15.5 | 12/31/2025 |
| Soleus Capital Management, L.P. | 3.30 | 4,500,000 | +0.0 | 03/31/2026 |
| LAURION CAPITAL MANAGEMENT LP | 2.85 | 3,882,162 | +0.0 | 03/31/2026 |
| Millennium Management LLC | 2.78 | 3,779,922 | +10.5 | 03/31/2026 |
| Morgan Stanley - Brokerage Accounts | 2.41 | 3,288,540 | +57.3 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| abrdn Healthcare Investors | 3.48 | 473,877 | +0.0 | 05/31/2026 |
| Vanguard Total Stock Mkt Idx Inv | 2.69 | 366,388 | -90.0 | 04/30/2026 |
| abrdn Life Sciences Investors | 2.22 | 302,891 | +0.0 | 05/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.